logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10517844 B1

PDFFull Text
Date of Patent:
Dec. 31, 2019

Filed:

Nov. 12, 2015

Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications

Applicant:

Buck Institute for Research on Aging, Novato, CA (US);

Inventors:

Gary K. Scott, Berkeley, CA (US);

Christopher C. Benz, Novato, CA (US);

Assignee:

Buck Institute for Research on Aging, Novato, CA (US);

Attorneys:

Tom Hunter

Weaver Austin Villeneuve & Sampson LLP

Primary Examiner:

Yate' K Cutliff

Int. Cl.
CPC ...
A61K 31/198 (2006.01); C07C 229/30 (2006.01); C07C 229/20 (2006.01); C07C 229/06 (2006.01); A61K 45/06 (2006.01); G01N 33/574 (2006.01); A61K 31/341 (2006.01); A61K 31/365 (2006.01); A61K 31/496 (2006.01); A61K 31/501 (2006.01); A61K 31/5377 (2006.01); A61K 31/713 (2006.01); C12N 15/113 (2010.01);
U.S. Cl.
CPC ...
A61K 31/198 (2013.01); A61K 45/06 (2013.01); C07C 229/06 (2013.01); C07C 229/20 (2013.01); C07C 229/30 (2013.01); G01N 33/57484 (2013.01); A61K 31/341 (2013.01); A61K 31/365 (2013.01); A61K 31/496 (2013.01); A61K 31/501 (2013.01); A61K 31/5377 (2013.01); A61K 31/713 (2013.01); C12N 15/1137 (2013.01); C12N 2310/14 (2013.01); C12N 2320/31 (2013.01); G01N 33/57415 (2013.01); G01N 2333/9065 (2013.01); G01N 2800/52 (2013.01);
Abstract

In various embodiments a cancer treatment method is provided based on inhibition of proline catabolism. When combined with p53 restoration therapy and/or inhibition of glutaminase, the inhibition of proline catabolism results in a 'synthetic lethal' and synergistic anticancer response. Novel suicide inhibitors that induce the degradation of proline dehydrogenase (PRODH) are also provided. Also provided is a method of assaying PRODH to identify responders/non-responders to inhibition of proline catabolism and/or glutaminase.

Find Patent Forward Citations

Scott, Gary. (2019). Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications (U.S. Patent No. 10517844). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/10517844

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…